- Home
- REVB vs NUWE Comparison
REVB vs NUWE Comparison
Compare REVB & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- NUWE
- Stock Information
- Founded
- REVB 2020
- NUWE 1999
- Country
- REVB United States
- NUWE United States
- Employees
- REVB N/A
- NUWE N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- REVB Health Care
- NUWE Health Care
- Exchange
- REVB Nasdaq
- NUWE Nasdaq
- Market Cap
- REVB 3.8M
- NUWE 3.9M
- IPO Year
- REVB N/A
- NUWE N/A
- Fundamental
- Price
- REVB $2.38
- NUWE $10.52
- Analyst Decision
- REVB
- NUWE Strong Buy
- Analyst Count
- REVB 0
- NUWE 1
- Target Price
- REVB N/A
- NUWE $714.00
- AVG Volume (30 Days)
- REVB 283.8K
- NUWE 2.3M
- Earning Date
- REVB 08-08-2025
- NUWE 08-12-2025
- Dividend Yield
- REVB N/A
- NUWE N/A
- EPS Growth
- REVB N/A
- NUWE N/A
- EPS
- REVB N/A
- NUWE N/A
- Revenue
- REVB N/A
- NUWE $8,787,000.00
- Revenue This Year
- REVB N/A
- NUWE $6.53
- Revenue Next Year
- REVB N/A
- NUWE $51.63
- P/E Ratio
- REVB N/A
- NUWE N/A
- Revenue Growth
- REVB N/A
- NUWE N/A
- 52 Week Low
- REVB $2.11
- NUWE $6.33
- 52 Week High
- REVB $168.00
- NUWE $175.98
- Technical
- Relative Strength Index (RSI)
- REVB 34.09
- NUWE 41.00
- Support Level
- REVB $2.97
- NUWE $12.81
- Resistance Level
- REVB $3.18
- NUWE $16.50
- Average True Range (ATR)
- REVB 0.22
- NUWE 2.05
- MACD
- REVB 0.05
- NUWE 0.64
- Stochastic Oscillator
- REVB 7.14
- NUWE 21.36
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.